SOX2 Is a Potential Novel Marker of Undifferentiated Thyroid Carcinomas

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2021 Jan 25

PMID 33489519

Citations 2

Authors

Wafaey Gomaa

Azmi Marouf

Asayil Alamoudi

Jaudah Al-Maghrabi

Affiliations

Soon will be listed here.

Abstract

Background Thyroid cancer is a very common endocrine malignancy. Cancer stem cells are attributable to initiation, progression, and treatment failure in thyroid carcinoma. In the current study, immunostaining of SRY-box 2 (SOX2) in thyroid carcinoma is investigated. Material and methods Tissue microarrays were generated from 219 thyroid carcinomas distributed as follows: papillary thyroid carcinoma (175), follicular thyroid carcinoma (11), medullary thyroid carcinoma (11), Hurthle cell carcinoma (three), poorly differentiated thyroid carcinoma (PTDC; nine), and anaplastic thyroid carcinoma (ATC; 10). Immunohistochemistry for SOX2 was done and examined for nuclear staining. The results were analysed. Results SOX2 immunostaining was positive in one PDTC (out of nine; 11.1%) and in three ATC (out of 10; 30%). The rest of the thyroid cancers showed no immunostaining for SOX2. Conclusion The study represents for the first time SOX2 immunostaining on a large number of thyroid carcinomas. We discovered that SOX2 immunostaining is found in PDTC and ATC while SOX2 immunostaining is lacking in other thyroid cancer. SOX2 may be a marker of loss of differentiation in thyroid carcinoma. In vitro as well as in vivo molecular studies are required to explore the possible role of SOX2 in thyroid carcinoma.

Citing Articles

Transcriptomic Differences in Medullary Thyroid Carcinoma According to Grade.

Ruz-Caracuel I, Caniego-Casas T, Alonso-Gordoa T, Carretero-Barrio I, Arino-Palao C, Santon A Endocr Pathol. 2024; 35(3):207-218.

PMID: 38958823 PMC: 11387449. DOI: 10.1007/s12022-024-09817-0.

The lncRNA RMST is drastically downregulated in anaplastic thyroid carcinomas where exerts a tumor suppressor activity impairing epithelial-mesenchymal transition and stemness.

De Martino M, Pellecchia S, Esposito F, Liotti F, Credendino S, Prevete N Cell Death Discov. 2023; 9(1):216.

PMID: 37393309 PMC: 10314909. DOI: 10.1038/s41420-023-01514-x.

References

Xiang R, Liao D, Cheng T, Zhou H, Shi Q, Chuang T . Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancer. Br J Cancer. 2011; 104(9):1410-7. PMC: 3101944. DOI: 10.1038/bjc.2011.94. View

Alonso M, Diez-Valle R, Manterola L, Rubio A, Liu D, Cortes-Santiago N . Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas. PLoS One. 2011; 6(11):e26740. PMC: 3206066. DOI: 10.1371/journal.pone.0026740. View

Fuziwara C, Saito K, Leoni S, Waitzberg A, Kimura E . The Highly Expressed FAM83F Protein in Papillary Thyroid Cancer Exerts a Pro-Oncogenic Role in Thyroid Follicular Cells. Front Endocrinol (Lausanne). 2019; 10:134. PMC: 6407429. DOI: 10.3389/fendo.2019.00134. View

Boumahdi S, Driessens G, Lapouge G, Rorive S, Nassar D, Mercier M . SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature. 2014; 511(7508):246-50. DOI: 10.1038/nature13305. View

Bauer J, Kopp S, Schlagberger E, Grosse J, Sahana J, Riwaldt S . Proteome Analysis of Human Follicular Thyroid Cancer Cells Exposed to the Random Positioning Machine. Int J Mol Sci. 2017; 18(3). PMC: 5372562. DOI: 10.3390/ijms18030546. View

Zhu F, Qian W, Zhang H, Liang Y, Wu M, Zhang Y . SOX2 Is a Marker for Stem-like Tumor Cells in Bladder Cancer. Stem Cell Reports. 2017; 9(2):429-437. PMC: 5550032. DOI: 10.1016/j.stemcr.2017.07.004. View

Sarkar A, Hochedlinger K . The sox family of transcription factors: versatile regulators of stem and progenitor cell fate. Cell Stem Cell. 2013; 12(1):15-30. PMC: 3608206. DOI: 10.1016/j.stem.2012.12.007. View

Lin R . Thyroid cancer stem cells. Nat Rev Endocrinol. 2011; 7(10):609-16. DOI: 10.1038/nrendo.2011.127. View

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1):11-30. DOI: 10.3322/caac.21166. View

10.

Vella V, Nicolosi M, Cantafio P, Massimino M, Lappano R, Vigneri P . DDR1 regulates thyroid cancer cell differentiation via IGF-2/IR-A autocrine signaling loop. Endocr Relat Cancer. 2018; 26(1):197-214. DOI: 10.1530/ERC-18-0310. View

11.

Jordan C, Guzman M, Noble M . Cancer stem cells. N Engl J Med. 2006; 355(12):1253-61. DOI: 10.1056/NEJMra061808. View

12.

Gharib H, Papini E, Paschke R . Thyroid nodules: a review of current guidelines, practices, and prospects. Eur J Endocrinol. 2008; 159(5):493-505. DOI: 10.1530/EJE-08-0135. View

13.

Santini R, Pietrobono S, Pandolfi S, Montagnani V, DAmico M, Penachioni J . SOX2 regulates self-renewal and tumorigenicity of human melanoma-initiating cells. Oncogene. 2014; 33(38):4697-708. PMC: 4180644. DOI: 10.1038/onc.2014.71. View

14.

Lundberg I, Edin S, Eklof V, Oberg A, Palmqvist R, Wikberg M . SOX2 expression is associated with a cancer stem cell state and down-regulation of CDX2 in colorectal cancer. BMC Cancer. 2016; 16:471. PMC: 4944515. DOI: 10.1186/s12885-016-2509-5. View

15.

Wuebben E, Rizzino A . The dark side of SOX2: cancer - a comprehensive overview. Oncotarget. 2017; 8(27):44917-44943. PMC: 5546531. DOI: 10.18632/oncotarget.16570. View

16.

Carina V, Zito G, Pizzolanti G, Richiusa P, Criscimanna A, Rodolico V . Multiple pluripotent stem cell markers in human anaplastic thyroid cancer: the putative upstream role of SOX2. Thyroid. 2013; 23(7):829-37. PMC: 3704189. DOI: 10.1089/thy.2012.0372. View

17.

Lin F, Lin P, Zhao D, Chen Y, Xiao L, Qin W . Sox2 targets cyclinE, p27 and survivin to regulate androgen-independent human prostate cancer cell proliferation and apoptosis. Cell Prolif. 2012; 45(3):207-16. PMC: 6495851. DOI: 10.1111/j.1365-2184.2012.00812.x. View

18.

Ferone G, Song J, Sutherland K, Bhaskaran R, Monkhorst K, Lambooij J . SOX2 Is the Determining Oncogenic Switch in Promoting Lung Squamous Cell Carcinoma from Different Cells of Origin. Cancer Cell. 2016; 30(4):519-532. PMC: 5065004. DOI: 10.1016/j.ccell.2016.09.001. View

19.

Warnke E, Pietsch J, Wehland M, Bauer J, Infanger M, Gorog M . Spheroid formation of human thyroid cancer cells under simulated microgravity: a possible role of CTGF and CAV1. Cell Commun Signal. 2014; 12:32. PMC: 4020378. DOI: 10.1186/1478-811X-12-32. View

20.

Lan L, Luo Y, Cui D, Shi B, Deng W, Huo L . Epithelial-mesenchymal transition triggers cancer stem cell generation in human thyroid cancer cells. Int J Oncol. 2013; 43(1):113-20. DOI: 10.3892/ijo.2013.1913. View